Envisioning Future Urinary Tract Infection Diagnostics

Robin Patel; Christopher R Polage; Jennifer Dien Bard; Larissa May; Francesca M Lee; Valeria Fabre; Mary K Hayden; Sarah D B Doernberg; David A Haake; Barbara W Trautner; Larissa Grigoryan; Ephraim L Tsalik; Kimberly E Hanson

doi:10.1093/cid/ciab749

Envisioning Future Urinary Tract Infection Diagnostics

Clin Infect Dis. 2022 Apr 9;74(7):1284-1292. doi: 10.1093/cid/ciab749.

Authors

Robin Patel^{1

2}, Christopher R Polage³, Jennifer Dien Bard^{4

5}, Larissa May⁶, Francesca M Lee⁷, Valeria Fabre⁸, Mary K Hayden⁹, Sarah D B Doernberg¹⁰, David A Haake¹¹, Barbara W Trautner¹², Larissa Grigoryan¹³, Ephraim L Tsalik¹⁴, Kimberly E Hanson¹⁵

Affiliations

¹ Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota, USA.
² Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
³ Department of Pathology, Duke University Health System, Durham, North Carolina, USA.
⁴ Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.
⁵ Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
⁶ Department of Emergency Medicine, University of California-Davis Health, Sacramento, California, USA.
⁷ Division of Infectious Diseases, Department of Pathology and Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
⁸ Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁹ Division of Infectious Diseases, Division of Internal Medicine, Rush Medical College, Chicago, IL, USA.
¹⁰ Division of Infectious Disease, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
¹¹ Infectious Diseases Section, VA Greater Los Angeles Healthcare System, and the Division of Infectious Diseases, Department of Medicine, the David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
¹² Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey Veterans Affairs Medical Center and Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
¹³ Center for Innovation in Quality Effectiveness and Safety, Michael E. DeBakay Veterans Affairs Medical Centetr; and and 15 Department of Family and Community Medicine, Baylor College of Medicine, Houston, Texas, USA.
¹⁴ Duke University Center for Applied Genomics and Precision Medicine, Durham, NC, USA; Durham Veterans Affairs Health Care System, Durham, North Carolina, USA.
¹⁵ Department of Internal Medicine and Department of Pathology, University of Utah, Salt Lake City, Utah, USA.

Abstract

Urinary tract infections (UTIs) are among the most common bacterial infections in the United States and are a major driver of antibiotic use, both appropriate and inappropriate, across healthcare settings. Novel UTI diagnostics are a strategy that might enable better UTI treatment. Members of the Antibacterial Resistance Leadership Group Laboratory Center and the Infectious Diseases Society of America Diagnostics Committee convened to envision ideal future UTI diagnostics, with a view towards improving delivery of healthcare, patient outcomes and experiences, and antibiotic use, addressing which types of UTI diagnostics are needed and how companies might approach development of novel UTI diagnostics.

Keywords: UTI; diagnostics; laboratory diagnosis; urinary tract infection.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Anti-Bacterial Agents / therapeutic use
Drug Resistance, Bacterial
Humans
United States
Urinary Tract Infections* / diagnosis
Urinary Tract Infections* / drug therapy
Urinary Tract Infections* / microbiology

Substances

Anti-Bacterial Agents

Grants and funding

UM1 AI104681/AI/NIAID NIH HHS/United States